Year: 2025

ViVac Appoints Keren Leshem as Chief Executive Officer, Strengthening Leadership to Advance RNA-Lipid Nanoparticle Immunotherapy Platform

JERUSALEM, Nov. 20, 2025 /PRNewswire/ -- ViVac Pharma Ltd., a pioneering synthetic biology company advancing RNA–Lipid Nanoparticle (LNP) immunotherapies, announces the...

error: Content is protected !!